The Ultrasonographic Evaluation of Abdominal Accessory Respiratory Muscle Thickness in Patients With Parkinson's Disease: Correlation With Disease Severity and Expiratory Respiratory Muscle Strength

NCT07308795 | Recruiting

• 1 other identifier: 2025-28
• Study Type: observational
• Target: 36
• Locations: 1 country
• Sites: 1

Brief Summary

Parkinson's disease is a neurodegenerative disorder characterized by both motor and non-motor symptoms. The involvement of respiratory muscles can lead to impairments in respiratory function in these patients. In this study is to evaluate the thickness of abdominal accessory respiratory muscles using ultrasonography in patients with Parkinson's disease. Additionally, the relationship between disease severity and expiratory respiratory muscle strength will be examined. The study will include Parkinson's patients at different stages of the disease, with respiratory muscle thickness measured via ultrasonography. The collected data will then be compared with disease severity and expiratory muscle strength.

Conditions

Parkinson Disease (PD); Maximum Inspiratory Pressure; Maximum Expiratory Pressure; Abdominal Accessory Respiratory Muscle Thickness

Keywords

abdominal muscles ultrasonography; parkinson disease; respiratory; MIP; abdominal muscles; respiratory muscles; expiratory muscle strenght; ultrasound; maximum expiratory pressure (MEP)

Outcome Measures

Primary Outcomes (3)

• Maximal Expiratory Pressure (MEP) Measurement

  MEP assesses the strength of abdominal and accessory expiratory muscles. During the maneuver, the patient is asked to blow forcefully into the mouthpiece for at least 1.5 seconds, as if inflating a balloon. The pressure generated during rapid expiration is measured by sensors, and after 1.5-2.0 seconds the shutter opens, ending the test. If multiple tests are conducted, the patient rests for at least 1 minute between trials, and a maximum of 3-5 trials are performed. Differences greater than 10 cmH₂O between trials are not accepted. The highest measurement is reported together with the predicted value. The MicroRPM Respiratory Pressure Meter (MicroDirect, USA) will be used.

  to be measured only once at the start day 1

• Maximal Inspiratory Pressure (MIP) Measurement

  MIP is used to assess the strength of inspiratory respiratory muscles. During the test, the patient is instructed to exhale down to residual volume. MIP is defined as the maximum negative pressure measured during a maximal inspiratory effort performed after reaching residual volume. Measurements will be taken using the MicroRPM Respiratory Pressure Meter (MicroDirect, USA).

  to be measured only once at the start day 1

• Ultrasonographic Assessment of Abdominal Accessory Respiratory Muscles

  Ultrasound measurements of the rectus abdominis, external oblique, internal oblique, and transversus abdominis muscles will be performed. Measurements will be taken in the supine position with the patient lying on their back, eyes facing upward, arms resting symmetrically beside the trunk, and lower extremities in full knee extension with an intermalleolar distance of 10 cm. Muscle thickness will be recorded at the end of normal expiration and at the end of forced expiration.

  to be measured only once at the start day 1

Other Outcomes (2)

• Six Minute Walk Test (6MWT)

  to be measured only once at the start day 1

• Modified Hoehn and Yahr Staging

  to be measured only once at the start day 1

Study Arms (2)

Parkinson Disease (PD)

Abdominal Accesory Respiratory Muscles (rectus abdominis, transversus abdominis, and oblique muscles) and MIP(maximum inspiratory pressure) MEP(maximum expiratory pressure) values of the group with Parkinson's diagnosis and Hoehn Yahr Stage 1-2-3 will be measured, a 6-Minute Walk Test will be performed and the results will be noted.

Control Group

Abdominal Accessory Respiratory Muscles (rectus abdominis, transversus abdominis, and oblique muscles) and MIP (maximum inspiratory muscles) MEP(maximum expiratory muscles) values of age and gender matched healthy values of age and gender matched healthy volunteers without any diagnosis of neuromuscular disease or chest diseases will be measured and the results will be noted.

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

THE GROUP WITH PARKINSON'S DIAGNOSIS AND HOEHN YAHR STAGE 1-2-3

You may qualify if:

• Age \> 18 years
• Parkinson's disease diagnosis with Modified Hoehn and Yahr stages 1-2-3
• Mini-Mental State Examination (MMSE) score \> 23
• Body Mass Index (BMI) \< 30

You may not qualify if:

• Active smokers
• Individuals with a diagnosis of active chest disease
• Those with hemodynamic instability
• Individuals with unstable vital signs
• Parkinson's patients who cannot be controlled with medical treatment
• Parkinson Plus syndromes

Sponsors & Collaborators

• Istanbul Physical Medicine Rehabilitation Training and Research Hospital: lead

Study Sites (1)

İstanbul Fizik Tedavi Ve Rehabilitasyon Eğitim Ve Araştirma Hastanesi

Istanbul, BAHÇELİEVLER, 34180, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Parkinson Disease

Condition Hierarchy (Ancestors)

Parkinsonian Disorders; Basal Ganglia Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases

Central Study Contacts

AYŞE NUR SARIKOÇ

CONTACT

+905412105141; aysenuryigit885@gmail.com

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Doctor

Study Record Dates

• First Submitted: December 8, 2025
• First Posted: December 30, 2025
• Study Start: December 29, 2025
• Primary Completion: February 28, 2026
• Study Completion: April 20, 2026
• Last Updated: January 2, 2026

Record last verified: 2025-12

Data Sharing

• IPD Sharing: Will not share

Locations

TU (1)